Payers Having More Impact On R&D, Pfizer Says; Asenapine Is Early Casualty

Pfizer's termination of its codevelopment agreement with Organon for the antipsychotic asenapine is indicative of the increasingly important role payer considerations play in development decisions, Pfizer CEO Jeffrey Kindler said